EU-AIMS scientists answer questions from the autism community about EU-AIMS autism research

20 November 2017

In this video EU-AIMS scientists answer questions from the autism community about EU-AIMS research.

Two public events organised by members of the EU-AIMS Ethics advisory board (lead by Ilina Singh, University of Oxford), one in the UK and one in Denmark were conducted as part of the consortium’s on-going PPI activities in 2014 and 2015.

Sixty-six individuals submitted written comments on the consortium’s research after these events, most were questions that autistic adults or parents of individuals with autism had raised. We summarised their questions in this video and put them to the scientists at the EU-AIMS 6th annual Meeting in 2017 in the following film:

What is EU-AIMS doing for Autism Research?

19 June 2015

The 3rd annual meeting was held on 13 -14 April 2015 at Paris (Servier), France. 130 consortium members attended the meeting.
Watch the EU-AIMS video  to get a better idea about the programme and what we are doing for autism research.

Autism: World's largest study aims to find best support

7 January 2015
BBC

Autism is a broad and varied condition which very little is known about.

BBC Disability Correspondent Nikki Fox has been given exclusive access to the world's largest study of autism, which hopes to discover how society can best support people with the disorder.

Scientists study how babies develop ADHD

17 April 2014
BBC

Scientists at a laboratory in central London are carrying out tests to try to discover how and why some people develop Attention Deficit Hyperactivity Disorder (ADHD).

The Birbeck Babylab studies how babies learn and has already made progress in understanding how autism develops in young children.

BBC London's Jean Mackenzie spoke to Dr Emily Jones, the lead researcher at the Birkbeck Babylab, and mothers Fiona Mackay and Sheryne Shillingford-Reed.

IMI and the EU-AIMS project - paving the way for new treatments for autism

13 January 2014

Around 1% of children are diagnosed with autism spectrum disorders (ASD), yet there are currently no drugs designed specifically to treat their main symptoms. Working to change this is the EU-AIMS project, which is supported by the Innovative Medicines Initiative (IMI). The goal of EU-AIMS is to generate tools that will enhance our understanding of ASD, and ultimately pave the way for the development of new, safe and effective treatments for use in both children and adults. As well as dramatically improving quality of life, good treatments would help to cut the social and economic costs of ASD.

The Innovative Medicines Initiative (IMI) is Europe's largest public-private initiative aiming to speed up the development of better and safer medicines for patients. IMI supports collaborative research projects and builds networks of industrial and academic experts in order to boost pharmaceutical innovation in Europe. IMI is a joint undertaking between the European Union and the pharmaceutical industry association EFPIA.

IMI - www.imi.europa.eu